Skip to content

Huashi Baidu Granule for Patients with Mild COVID-19: A Single-center, Retrospective Cohort Study

Huashi Baidu Granule for Patients with Mild COVID-19: A Retrospective Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060472
Enrollment
Unknown
Registered
2022-06-02
Start date
2022-05-23
Completion date
Unknown
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Control group:Conventional therapy

Sponsors

Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. In accordance with the diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Version 9) issued by the National Health Commission on the diagnosis and treatment of mild cases of novel coronavirus pneumonia; 2. Confirmed by nucleic acid test of novel coronavirus; 3. Mild clinical manifestations such as low fever, slight fatigue, olfactory and taste disorders.

Exclusion criteria

Exclusion criteria: 1. Patients with serious primary diseases of cardiovascular, cerebrovascular, lung, kidney and hematopoietic systems; 2. Pregnant or lactating patients; 3. Allergic to prescribed drugs.

Design outcomes

Primary

MeasureTime frame
Time of virus nucleic acid test turning negative;The hospitalization time;

Secondary

MeasureTime frame
Symptom improvement rate;

Countries

China

Contacts

Public ContactFang Bangjiang

Longhua Hospital, Shanghai University of Traditional Chinese Medicine

fangbji@163.com+86 18917763257

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026